anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Abnormal Coagulation Profile 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Haemophilia 8. Young Adult 19-24 years 9. Hereditary Factor IX Deficiency 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Hodgkins Lymphoma 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Deferasirox for managing iron overload in people with thalassaemia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Iron Excess 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Thalassemia 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Fluid replacement therapy for acute episodes of pain in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Pain 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Pathogen‐reduced platelets for the prevention of bleeding
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Platelet transfusion 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Hodgkins Lymphoma 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
1. Aged 80 and over 80+ years 2. Hodgkin's Disease Stage I 3. Adult 19-44 years 4. Hodgkins Lymphoma 5. Middle Aged 45-64 years 6. Hodgkin's Disease Stage II 7. Young Adult 19-24 years 8. Aged 65-79 years
Provide patient population that should be included in the study
Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Thromboembolic Event 6. Aged 65-79 years
Provide patient population that should be included in the study
Exercise for haemophilia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Haemophilia 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for treating community‐acquired pneumonia in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Community Acquired Pneumonia 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Beta Thalassemia Intermedia 5. Infant 1 to 23 mo 6. Thalassemia 7. Hemoglobin E/beta Thalassemia Disease 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Thrombocytopenia 4. Child 6-12 years 5. Infant 1 to 23 mo 6. Chronic Failure 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Bone marrow failure 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Bisphosphonate therapy for osteogenesis imperfecta
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Osteogenesis Imperfecta 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Caregiver 8. Aged 65-79 years 9. Hemoglobin SS Disease 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Bortezomib for the treatment of multiple myeloma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Multiple Myeloma
Provide patient population that should be included in the study
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Thrombocytopenia 4. Adult 19-44 years 5. Child 6-12 years 6. Blood disorders 7. Middle Aged 45-64 years 8. Infant 1 to 23 mo 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Subsidising artemisinin‐based combination therapy in the private retail sector
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Oral iron supplements for children in malaria‐endemic areas
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Malaria 5. Anemia 6. Birth to 1 mo 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Myelodysplastic Syndrome 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Piracetam for reducing the incidence of painful sickle cell disease crises
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Meditation for adults with haematological malignancies
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hematological Malignancy 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Washed versus unwashed red blood cells for transfusion for the prevention of morbidity and mortality in preterm infants
1. Very Preterm Infant (28-31 weeks) 2. Birth to 1 mo 3. Very Low Birth Weight Infant 4. Preterm Infant
Provide patient population that should be included in the study
Antibody therapies for lymphoma in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Hodgkins Lymphoma 4. Non-hodgkin's Lymphoma 5. Lymphoproliferative disorder 6. Infant 1 to 23 mo 7. Birth to 1 mo 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Adult 19-44 years 8. Chemotherapy 9. Middle Aged 45-64 years 10. Young Adult 19-24 years 11. Birth to 1 mo 12. Hematological Malignancy 13. Malignant Solid Tumour 14. Cancer
Provide patient population that should be included in the study
Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Sickle Cell Crisis 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Haemophilia 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Thrombocytopenia 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Central Venous Catheterisation 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Blood disorders 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Acute myeloid leukaemia (in remission) 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Blood disorders 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Adult 19-44 years 8. Hodgkins Lymphoma 9. Non-hodgkin's Lymphoma 10. Middle Aged 45-64 years 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Multiple Myeloma
Provide patient population that should be included in the study
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Bone marrow failure 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Blood disorders 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Acute Myelocytic Leukemia 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell transplantation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Hemopoietic Stem Cell Transplant 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological therapies for sickle cell disease and pain
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Myelofibrosis 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Sapropterin dihydrochloride for phenylketonuria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Phenylketonuria 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Enzyme replacement and substrate reduction therapy for Gaucher disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Gaucher's Disease 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Protein substitute for children and adults with phenylketonuria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Phenylketonuria 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Phenylalanine Restricted Diet 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Artemisinin‐naphthoquine for treating uncomplicated Plasmodium falciparum malaria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Falciparum Malaria 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Blood Coagulation Disorder 8. Surgery 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Hodgkin's disease unclassifiable 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Paroxysmal Nocturnal Hemoglobinuria 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Deferasirox for managing iron overload in people with myelodysplastic syndrome
1. Aged 80 and over 80+ years 2. Iron overload 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Myelodysplastic Syndrome 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Prevention Of Malaria 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for treating acute bleeding episodes in people with acquired hemophilia A
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acquired haemophilia 5. Young Adult 19-24 years 6. Acute bleeding 7. Aged 65-79 years
Provide patient population that should be included in the study
Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic hematopoietic stem cell transplantation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Allogeneic Stem Cell Transplantation 6. Aged 65-79 years
Provide patient population that should be included in the study
The role of additional radiotherapy for primary central nervous system lymphoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Primary Central Nervous System Lymphoma 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Deferasirox for managing transfusional iron overload in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Malaria 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Malaria 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Vivax Malaria 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Oropharyngeal Cancer 10. Malignant Tumor Of Oral Cavity 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Hyperbaric oxygen therapy for late radiation tissue injury
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Late Effect Of Radiation Therapy 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Adverse Effect Of Radiation Therapy 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Non-small cell lung cancer 6. Non-small cell lung cancer stage III 7. Non-small cell lung cancer stage IV 8. Aged 65-79 years
Provide patient population that should be included in the study
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Ovarian epithelial cancer recurrent
Provide patient population that should be included in the study
Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Rectal Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Colorectal Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Renal cell carcinoma 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ovarian epithelial cancer 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Aged 65-79 years 4. Healthy
Provide patient population that should be included in the study
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer
1. Aged 80 and over 80+ years 2. Endometrial Cancer 3. Adult 19-44 years 4. Obesity 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Overweight
Provide patient population that should be included in the study
Skin‐sparing mastectomy for the treatment of breast cancer
1. Ductal Carcinoma In Situ
Provide patient population that should be included in the study
Exercise interventions for adults with cancer receiving radiation therapy alone
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Radiotherapy 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Prostate Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery
1. Aged 80 and over 80+ years 2. Hemicolectomy 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Transverse Colectomy 6. Surgical Reanastomosis Of Colon 7. Young Adult 19-24 years 8. Rectal resection 9. Proctocolectomy 10. Aged 65-79 years 11. Sigmoid Colectomy
Provide patient population that should be included in the study
Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fatigue 6. Advanced Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Neoadjuvant treatment for stage III and IV cutaneous melanoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Skin melanoma 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Febrile Neutropenia 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation
1. Adult 19-44 years 2. Radiotherapy To Head 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years 6. Cancer 7. Cognitive impairment
Provide patient population that should be included in the study
Preoperative exercise training for people with non‐small cell lung cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Lung Excision 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Non-small cell lung cancer 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Antineoplastic Chemotherapy Regimen 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Cancer
Provide patient population that should be included in the study
Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cervical Cancer 5. Young Adult 19-24 years 6. Regional Lymph Node Metastasis Present 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Palliative Care 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Bowel Dysfunction 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Cancer
Provide patient population that should be included in the study
Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Ovarian epithelial cancer 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cervical Cancer 5. Young Adult 19-24 years 6. Advanced Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Asymptomatic 6. Aged 65-79 years
Provide patient population that should be included in the study
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chemotherapy 4. Fallopian tube neoplasm 5. Middle Aged 45-64 years 6. Disease Recurrence 7. Young Adult 19-24 years 8. Epithelial Tumor Of Ovary 9. Aged 65-79 years 10. Malignant Tumor Of Peritoneum 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Oxycodone for cancer‐related pain
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cancer Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Perioperative enhanced recovery programmes for women with gynaecological cancers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Elective Surgery 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Gynaecological cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Gases for establishing pneumoperitoneum during laparoscopic abdominal surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Laparoscopic Surgery 4. Abdominal surgery 5. Child 6-12 years 6. Infant 1 to 23 mo 7. Operation On Female Genital Organs 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Adult 19-44 years 11. Procedure On Pelvis 12. Middle Aged 45-64 years 13. Young Adult 19-24 years 14. Birth to 1 mo
Provide patient population that should be included in the study
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Malignant Epithelial Ovarian Carcinoma 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Malignant Epithelial Ovarian Carcinoma 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy
1. Pancreatic cancer 2. Pancreatitis 3. Pancreaticoduodenectomy 4. Pancreatic neoplasms
Provide patient population that should be included in the study
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Breast Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Carer Able To Cope 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Primary Malignant Neoplasm Of Brain
Provide patient population that should be included in the study
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Malignant Tumor Of Oral Cavity 10. Oropharyngeal Cancer 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic abdominal drainage for pancreatic surgery
1. Aged 80 and over 80+ years 2. Pancreatic disorder 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Infant 1 to 23 mo 6. Young Adult 19-24 years 7. Birth to 1 mo 8. Aged 65-79 years
Provide patient population that should be included in the study
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Non-small cell lung cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer
1. Aged 80 and over 80+ years 2. Non-muscle invasive bladder cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chemotherapy 4. Middle Aged 45-64 years 5. Nausea And Vomiting 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Cancer
Provide patient population that should be included in the study
Perioperative systemic nonsteroidal anti‐inflammatory drugs (NSAIDs) in women undergoing breast surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Breast Conserving Surgery 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Music interventions for improving psychological and physical outcomes in people with cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Cancer
Provide patient population that should be included in the study
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Cancer
Provide patient population that should be included in the study
Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Chemotherapy 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Central Venous Catheterisation 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Cancer
Provide patient population that should be included in the study
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Multiple Myeloma
Provide patient population that should be included in the study
School‐based physical activity programs for promoting physical activity and fitness in children and adolescents aged 6 to 18
1. Child 6-12 years 2. Adolescent 13-18 years
Provide patient population that should be included in the study
Roux‐en‐Y versus Billroth‐I reconstruction after distal gastrectomy for gastric cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Gastrectomy 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cholangiocarcinoma Of Biliary Tract 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions targeted at women to encourage the uptake of cervical screening
1. Aged 80 and over 80+ years 2. Screening For Malignant Neoplasm Of Cervix 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Young Adult 19-24 years 5. Ewing's sarcoma 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Partial breast irradiation versus whole breast radiotherapy for early breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Breast Conserving Surgery 5. Young Adult 19-24 years 6. Early Breast Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Hydromorphone for cancer pain
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Cancer Pain 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Degarelix for treating advanced hormone‐sensitive prostate cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Prostate Cancer 6. Advanced Cancer 7. Aged 65-79 years
Provide patient population that should be included in the study
Physical therapy interventions, other than general physical exercise interventions, in children and adolescents before, during and following treatment for cancer
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Young Adult 19-24 years 5. Birth to 1 mo 6. Adolescent 13-18 years 7. Cancer
Provide patient population that should be included in the study
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ovarian epithelial cancer 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Protons versus photons for the treatment of chordoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Primary Malignant Neoplasm Of Bone Of Skull 6. Radiotherapy 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Intravesical gemcitabine for non‐muscle invasive bladder cancer
1. Aged 80 and over 80+ years 2. Non-muscle invasive bladder cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Non-small cell lung cancer 5. Advanced Cancer
Provide patient population that should be included in the study
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Locally Advanced Breast Cancer 5. Young Adult 19-24 years 6. Metastatic breast cancer 7. Breast Cancer 8. Aged 65-79 years
Provide patient population that should be included in the study
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Epidermal Growth Factor Receptor Increased 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise for cancer cachexia in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cachexia 6. Aged 65-79 years 7. Cancer
Provide patient population that should be included in the study
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Recurrent Tumor 5. Cervical Cancer 6. Young Adult 19-24 years 7. Metastasis 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Paravertebral anaesthesia with or without sedation versus general anaesthesia for women undergoing breast cancer surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Locally Advanced Breast Cancer 5. Surgery 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Recurrent Tumor 5. Young Adult 19-24 years 6. Glioblastoma 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Tamoxifen 6. Breast Cancer 7. Aged 65-79 years
Provide patient population that should be included in the study
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Prostate Cancer Metastatic 5. Aged 65-79 years
Provide patient population that should be included in the study
Body weight management in overweight and obese breast cancer survivors
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Obesity 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Breast Cancer 7. Aged 65-79 years
Provide patient population that should be included in the study
Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
1. Primary Malignant Neoplasm Of Prostate Metastatic To Bone 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Platinum‐containing regimens for triple‐negative metastatic breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Triple-negative breast cancer
Provide patient population that should be included in the study
Targeted therapy for metastatic renal cell carcinoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Metastatic Renal Cell Carcinoma
Provide patient population that should be included in the study
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Acute Lymphoblastic Leukaemia 6. Thromboembolism 7. Aged 65-79 years
Provide patient population that should be included in the study
The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with advanced illness and their caregivers
1. Aged 80 and over 80+ years 2. Terminal Illness 3. Adult 19-44 years 4. Life-threatening Illness or event 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Caregiver 8. Hospitalization 9. Advanced Cancer 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Retzius‐sparing versus standard robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Prostate Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Helicobacter pylori eradication for the prevention of gastric neoplasia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Helicobacter Pylori Antibody Positive 8. Aged 65-79 years 9. Healthy 10. Adolescent 13-18 years